Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 30, 2003 (Second Quarter of Fiscal 2003)
Business Overview: Cooper operates two primary segments: CooperVision (CVI), which markets specialty contact lenses, and CooperSurgical (CSI), which markets medical devices and surgical instruments for gynecologists and obstetricians.
Key Financial Metrics
| Metric | Three Months Ended Apr 30, 2003 |
Six Months Ended Apr 30, 2003 |
Six Months Ended Apr 30, 2002 |
|---|---|---|---|
| Net Sales | $96.4 million | $190.4 million | $130.0 million |
| Gross Profit | $62.4 million | $121.8 million | $81.6 million |
| Gross Margin | 65% | 64% | 63% |
| Operating Income | $21.2 million | $41.0 million | $27.8 million |
| Net Income | $15.2 million | $29.1 million | $19.3 million |
| Diluted EPS | $0.48 | $0.92 | $0.62 |
| Operating Cash Flow | N/A | $30.1 million | $24.7 million |
| Total Debt | $162.6 million | $162.6 million | $163.7 million |
| Cash & Equivalents | $11.9 million | $11.9 million | $17.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 34% in the quarter and 46% year-to-date compared to the prior year. CVI sales grew 39% (quarter) and 54% (YTD), while CSI sales grew 16% (quarter) and 24% (YTD).
- Profitability: Operating income rose 44% in the quarter and 47% YTD. Gross margins improved to 65% (quarter) and 64% (YTD), driven by cost reductions and a shift toward higher-margin specialty contact lenses.
- EPS Expansion: Diluted earnings per share increased 50% in the quarter and 48% YTD.
- Acquisitions: Significant growth was driven by the integration of Biocompatibles (acquired Feb 2002) and recent CSI acquisitions (Norland, Ackrad, Sage). A subsequent acquisition of Prism Enterprises was completed in May 2003.
- Expense Increases: Selling, general, and administrative (SGA) expenses rose 41% YTD, largely due to acquisition-related costs and currency fluctuations. R&D expenses increased 46% YTD due to new product development initiatives.
Guidance, Outlook, and Risks
- Liquidity: Management expects cash on hand ($11.9 million) plus operating cash flow to fund operations, capital expenditures, dividends, and smaller acquisitions. The company has $64.7 million available under its KeyBank line of credit.
- Tax Outlook: The effective tax rate is estimated at 25% for fiscal 2003. Due to net operating loss (NOL) carryforwards, the company anticipates minimal cash tax payments until approximately 2006.
- Dividends: A semiannual dividend of $0.03 per share was declared on May 16, 2003, payable July 3, 2003.
- Risks:
- Foreign Exchange: Exposure to fluctuations in the British pound and euro, which impacts both revenue and manufacturing costs.
- Interest Rates: Variable interest rates on debt tied to LIBOR.
- Integration: Risks associated with integrating recent acquisitions and achieving projected synergies.
- Legal: A trademark dispute with Dioptics Medical Products was settled in May 2003; a provision was recorded in the first quarter.
Investor Verification Checklist
- Acquisition Impact: Verify the extent to which revenue growth is organic versus acquisition-driven (specifically Biocompatibles and CSI acquisitions).
- Currency Sensitivity: Assess the net impact of foreign exchange rates on gross margins, as manufacturing costs in the UK may offset revenue gains from a stronger pound.
- Debt Structure: Review the terms of the KeyBank line of credit and the impact of variable interest rates on future interest expense.
- Tax Strategy: Confirm the timeline for exhausting NOL carryforwards and the potential for increased cash tax payments post-2006.
- Product Mix: Monitor the shift from commodity to specialty lenses (toric, multifocal, cosmetic) as a driver of margin expansion.